144 related articles for article (PubMed ID: 15564290)
1. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats.
Oyama K; Fujimura T; Ninomiya I; Miyashita T; Kinami S; Fushida S; Ohta T; Koichi M
Carcinogenesis; 2005 Mar; 26(3):565-70. PubMed ID: 15564290
[TBL] [Abstract][Full Text] [Related]
2. [A COX-2 inhibitor suppresses esophageal inflammation-metaplasia-adenocarcinoma sequence in rats].
Miwa K; Oyama K; Fujimura T
Nihon Rinsho; 2005 Aug; 63(8):1387-93. PubMed ID: 16101227
[TBL] [Abstract][Full Text] [Related]
3. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Esquivias P; Morandeira A; Escartín A; Cebrián C; Santander S; Esteva F; García-González MA; Ortego J; Lanas A; Piazuelo E
World J Gastroenterol; 2012 Sep; 18(35):4866-74. PubMed ID: 23002358
[TBL] [Abstract][Full Text] [Related]
4. [Cyclooxygenase (COX)-2 expression in a rat duodenoesophageal reflux model and chemoprevention of adenocarcinoma by the selective COX-2 inhibitor nimesulide].
Oyama K; Fujimura T; Ninomiya I; Miyashita T; Kinami S; Fushida S; Ohta T
Nihon Shokakibyo Gakkai Zasshi; 2007 Aug; 104(8):1183-91. PubMed ID: 17675820
[TBL] [Abstract][Full Text] [Related]
5. Dietary zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
Fong LY; Zhang L; Jiang Y; Farber JL
J Natl Cancer Inst; 2005 Jan; 97(1):40-50. PubMed ID: 15632379
[TBL] [Abstract][Full Text] [Related]
6. Ingestion of thioproline suppresses rat esophageal adenocarcinogenesis caused by duodenogastroesophageal reflux.
Sasaki S; Miwa K; Fujimura T; Oba M; Miyashita T; Kinami S
Oncol Rep; 2007 Dec; 18(6):1443-9. PubMed ID: 17982628
[TBL] [Abstract][Full Text] [Related]
7. Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus.
Carlton PS; Gopalakrishnan R; Gupta A; Liston BW; Habib S; Morse MA; Stoner GD
Cancer Res; 2002 Aug; 62(15):4376-82. PubMed ID: 12154043
[TBL] [Abstract][Full Text] [Related]
8. [An experimental study on chemoprevention of esophageal adenocarcinoma by celecoxib, a selective cyclooxygenase-2 inhibitor].
Zhang T; Su LW; Zhu YF; Lang HJ; Zhang F; Zhou YA; Liang XH; Wang YJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2012 May; 15(5):512-6. PubMed ID: 22648851
[TBL] [Abstract][Full Text] [Related]
9. [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
Tang BD; Zeng ZR; Hu PJ
Ai Zheng; 2006 Oct; 25(10):1205-9. PubMed ID: 17059761
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in F344 rats.
Li ZG; Shimada Y; Sato F; Maeda M; Itami A; Kaganoi J; Komoto I; Kawabe A; Imamura M
Int J Oncol; 2002 Dec; 21(6):1275-83. PubMed ID: 12429978
[TBL] [Abstract][Full Text] [Related]
11. The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.
Stoner GD; Qin H; Chen T; Carlton PS; Rose ME; Aziz RM; Dixit R
Carcinogenesis; 2005 Sep; 26(9):1590-5. PubMed ID: 15878914
[TBL] [Abstract][Full Text] [Related]
12. Duodenal juice stimulates oesophageal stem cells to induce Barrett's oesophagus and oesophageal adenocarcinoma in rats.
Miyashita T; Ohta T; Fujimura T; Ninomiya I; Fushida S; Hattori T; Miwa K
Oncol Rep; 2006 Jun; 15(6):1469-75. PubMed ID: 16685381
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor.
Oba M; Miwa K; Fujimura T; Harada S; Sasaki S; Hattori T
Int J Cancer; 2008 Oct; 123(7):1491-8. PubMed ID: 18646190
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Buttar NS; Wang KK; Leontovich O; Westcott JY; Pacifico RJ; Anderson MA; Krishnadath KK; Lutzke LS; Burgart LJ
Gastroenterology; 2002 Apr; 122(4):1101-12. PubMed ID: 11910360
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
Yu HP; Shi LY; Lu WH; Su YH; Li YY; Xu SQ
J Gastroenterol Hepatol; 2004 Jun; 19(6):638-42. PubMed ID: 15151617
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW
J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696
[TBL] [Abstract][Full Text] [Related]
19. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest.
Cheong E; Ivory K; Doleman J; Parker ML; Rhodes M; Johnson IT
Carcinogenesis; 2004 Oct; 25(10):1945-52. PubMed ID: 15155531
[TBL] [Abstract][Full Text] [Related]
20. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
